Evidence map›Paper›PMID 22872030›Full record

Trial reportEuropean journal of clinical nutrition2012

The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study.

B Leber, N J Tripolt, D Blattl, M Eder, T C Wascher, T R Pieber, R Stauber, H Sourij, K Oettl, V Stadlbauer

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical nutrition, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03418857 (The Role of Probiotics in Attenuating Inflammation and Improving Gut Health in Obese Adults), which is not on this map. Cited by 55 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 7 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03418857 phase1 / phase2recruitingnot on this mapstarted 2018, after this paper: background citation

The Role of Probiotics in Attenuating Inflammation and Improving Gut Health in Obese Adults

TypeinterventionalSponsorPenn State UniversityRan2018 to 2022Enrolled40ConditionsMetabolic SyndromeArmsYogurt smoothie with BB-12, Yogurt smoothie
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 7 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. The Effect of Supplementation withJournal of research in pharmacy practice · 2026
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

B LeberDivision of Transplantation Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
N J Tripolt
D Blattl
M Eder
T C Wascher
T R Pieber
R Stauber
H Sourij
K Oettl
V Stadlbauer
Medical University of Graz · ATHanusch Hospital · AT

Funding

Austrian Science Fund FWF P 24362
6 · The paper itself

Abstract

BACKGROUND/

objectivesObesity and metabolic disorders are linked to inflammation via gut microbiota and/or gut permeability. Gut-derived endotoxin triggers inflammation leading to metabolic syndrome (MetS) and contributing to oxidative stress. We intended to investigate the effect of Lactobacillus casei Shirota on gut permeability, presence of endotoxin and neutrophil function in MetS. SUBJECTS/

methodsPatients with MetS were randomized to receive 3 × 6.5 × 10⁹ CFU L. casei Shirota (probiotic group) or not for 3 months. Gut permeability was assessed by a differential sugar absorption method and by determination of diaminooxidase serum levels, endotoxin by an adapted limulus amoebocyte lysate assay, neutrophil function and toll-like receptor (TLR) expression by flow cytometry and ELISA was used to detect lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14) levels.

resultsTwenty-eight patients and 10 healthy controls were included. Gut permeability was significantly increased in MetS compared with controls but did not differ between patient groups. None of the patients were positive for endotoxin. LBP and sCD14 levels were not significantly different from healthy controls. High-sensitive C-reactive protein and LBP levels slightly but significantly increased after 3 months within the probiotics group. Neutrophil function and TLR expression did not differ from healthy controls or within the patient groups.

conclusionsGut permeability of MetS patients was increased significantly compared with healthy controls. L. casei Shirota administration in the MetS patients did not have any influence on any parameter tested possibly due to too-short study duration or underdosing of L. casei Shirota.

Indexed as

Acute-Phase ProteinsAdultAgedAmine Oxidase (Copper-Containing)Carrier ProteinsCohort StudiesC-Reactive ProteinEndotoxinsFemaleHumansIntestinal MucosaLacticaseibacillus caseiLipopolysaccharide-Binding ProteinLipopolysaccharide ReceptorsMaleMembrane GlycoproteinsAcute-Phase ProteinsAmine Oxidase (Copper-Containing)Carrier ProteinsC-Reactive ProteinEndotoxinsLipopolysaccharide-Binding ProteinLipopolysaccharide ReceptorsMembrane Glycoproteins

Identifiers

PMID22872030
OpenAlexW2023580481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.